Sorry, you need to enable JavaScript to visit this website.
Pfizer’s Drug Safety R&D group develops and applies the skills, experience and scientific tools necessary for safety assessment and risk management of targets and compounds across the research, development and commercial phases of drug development. We seek to enhance our capabilities for target safety assessment, selection of safer compounds, toxicity risk management and translation of preclinical models.


We are interested in establishing alliances to develop and access:

  • Mechanisms, translatable and monitorable biomarkers, and screening approaches related to target organ toxicity
    • Cardiovascular safety including vascular injury and early detection of cardiotoxicity
    • CNS biomarkers including peripheral neuropathy
    • Liver injury in particular immune-mediated DILI and transporters
    • Immunostimulation, including hypersensitivity, autoimmunity, cytokine release
    • Nephrotoxicity – glomerular and tubular
    • Skeletal and cardiac muscle toxicity
    • Pancreatic toxicity
    • Ocular safety
    • Screening for abuse potential
  • Animal models, biomarkers and screening approaches for preclinical immuno-oncology investigation, supporting mono- and combination-therapy approaches (interpretation and translatability)
    • Immune system components and responses comparability between preclinical species and human
  • Biotherapeutics-related analytical technologies
    • Immunogenicity and other safety-relevant assays
    • Assays related to aggregation, subvisible particles
  • 3D and complex models including stem cell approaches and microfluidics
  • Deeper knowledge of targets and pathways
    • Knock-in, knock-out technologies
    • Novel technologies and increased throughput for target localization studies
    • Novel technologies and increased throughput for target localization studies
  • Safety biomarker technologies/enablers
    • Emerging platforms, including miRNA-based multiplex; analytical approaches
    • Academic collaborations to leverage annotated biofluid collections to understand target organ toxicities and enable clinical translation
  • Advancing Regulatory Science
    • Systems pharmacology approaches for prediction of adverse events
    • Novel in silico modelling approaches for pro-arrhythmia detection

Not actively seeking partnering opportunities in:

  • Genetox Screening
  • hERG related assays
  • In vitro screening models without significant validation